Challenges to Research and Innovation to Optimize Deceased Donor Organ Quality and Quantity Peter Abt, MD Sandy Feng, MD PhD American Society of Transplant.

Slides:



Advertisements
Similar presentations
Board Governance: A Key to Quality Organizations
Advertisements

TISSUE BANKING Challenging to Say the Least
Donald T. Simeon Caribbean Health Research Council
Le-Edged Sword Risks, Rewards and the Double-Edged Sword: Views of Pharmacogenetic Testing and Research in the Alaska Native/American Indian Community.
LEGAL ISSUES IN AUTHORIZATION FOR ORGAN DONATION IN MISSOURI & KANSAS Laurence R. Tucker November 18, 2011.
MEDICINES SELECTION & FORMULARY MANAGEMENT
Alexandra K. Glazier, JD, MPH Why Gift Law Matters: The Law and Ethics of Donor Designation Next Speaker: Sponsored by.
Behavioral Research Chapter Three Ethical Research.
Obtaining Informed Consent: 1. Elements Of Informed Consent 2. Essential Information For Prospective Participants 3. Obligation for investigators.
Subject Selection and Recruitment David Wendler Department of Clinical Bioethics NIH, USA.
Ad Hoc Disease Transmission Advisory Committee Spring 2015.
How does the process work? Submissions in 2007 (n=13,043) Perspectives.
The Pursuit of Better Medicines through Genetic Research Terri Arledge, DVM US Department Head Drug Development Genetics.
CUMC IRB Investigator Meeting November 9, 2004 Research Use of Stored Data and Tissues.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
DONATION AND TRANSPLANTATION COMMUNITY OF PRACTICE GOAL MESSAGING: 5000 IN FIVE.
Proposal to Modify Existing or Establish New Requirements for the Informed Consent of Living Donors (Resolution 18) Living Donor Committee Mary Amanda.
Title slide PIPELINE QRA SEMINAR. PIPELINE RISK ASSESSMENT INTRODUCTION TO GENERAL RISK MANAGEMENT 2.
Scientific Data Management for the Protection of Human Subjects Robert R. Downs NASA Socioeconomic Data and Applications Center (SEDAC) Center for International.
Good Clinical Practice GCP
Internal Auditing and Outsourcing
Care Options for NHS Continuing Health Care (CHC) Wirral PCT Board – 12 February 2008 Tina Long - Director of Strategic Partnerships Sheila Hillhouse -
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
Performance Measurement and Analysis for Health Organizations
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
Help us Help you: IRB Policy Updates Susan Bankowski, MS, JD IRB Chair.
Implications for the Use of Tissue in Research P. Pearl O’Rourke, MD Partners HealthCare Boston, MA.
Role of the Oncology Research Team Carmen B. Jacobs, BS, RN,OCN, CCRP U.T.M.D. Anderson Cancer Center Houston, Texas U.S.A.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Spring 2015.
Department of Health and Human Services Office of the Assistant Secretary for Health (ASH) Advisory Committee on Blood Safety and Availability (ACBSA)
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
Policy track summary ICIUM 2011 – 18 Nov Policy track topics 1.The pharmaceutical policy process 2.Quality and safety of medicines in LMIC 3.Policy.
OPTN Strategic Plan Maureen McBride United Network for Organ Sharing August 28, 2012.
Missing Data in NSQIP Albumin Peter Doris SQAN. Clarification Albumen –Egg white Albumin –A water soluble protein.
The Paradox in HIPAA Deven McGraw, JD, MPH, LLM Partner Manatt, Phelps & Phillips, LLP December 8, 2014.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE PCORI Board of Governors Meeting Washington, DC September 24, 2012 Anne Beal, MD, MPH, Chief Operating Officer.
Who we are What we do Where we are going How you can help.
OPTN OPTN/UNOS Ethics Committee Spring 2012 Regional Meeting Update Chair, Alexandra Glazier, MPH, JD Vice-Chair, Peter Reese, MD.
Dispensary and Administration Site Information Presentation.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Advisory Committee on Organ Transplantation (ACOT) November 17, 2015
Investigational Devices and Humanitarian Use Devices June 2007.
Introduction Organ Transplantation Program Update Advisory Committee on Organ Transplantation November 17, 2015 Melissa Greenwald, MD Acting Director Division.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
Chapter 5 Ethical Concerns in Research. Historical Perspective on Ethics Nazi Experimentation in WWII –“medical experiments” –Nuremberg War Crime Trials.
Second Annual Medical Research Summit March 25, 2002 Washington, D.C.
Overcoming challenges in pediatric oncology product development: Regulatory oversight of multi-national clinical studies Ursula Kern, Advisory Committees.
Delivery System Reform Incentive Payment Program (“DSRIP”) New York Presbyterian Performing Provider System.
Accountability & Program Assessment Governing Board Online Training Module.
Quality Metrics of Performance of Research Ethics Committees Cristina E. Torres, PhD FERCAP Coordinator.
GCP (GOOD CLINICAL PRACTISE)
A capacity building programme for patient representatives
White Paper: Ethical Considerations of Imminent Death Donation
Patricia M. Alt, Ph.D. Dept. of Health Science Towson University
FDA’s IDE Decisions and Communications
MUHC Innovation Model.
Within Trial Decisions: Unblinding and Termination
Leigh E. Tenkku, PhD, MPH Department of Family and Community Medicine
NHLBI Perspective Yves Rosenberg, M.D, M.P.H.
Organ Procurement Organization Committee Report
Modify HOPE Act Variance to Include Other Organs
AGREEMENT FOR TRANSPARENCY The Case of Mexico
Opening an IND: Investigator Perspective
Vascularized Composite Allograft Transplantation Committee Fall 2014
Office of Research Integrity and Protections
Presentation transcript:

Challenges to Research and Innovation to Optimize Deceased Donor Organ Quality and Quantity Peter Abt, MD Sandy Feng, MD PhD American Society of Transplant Surgeons August 28, 2012

Organ Quantity Limits Transplant Opportunities  Primary limitation to transplantation Motivates living donor transplantation  Engenders waitlist morbidity and mortality

Organ Quality Limits Transplant Outcomes  Decrease in ideal donors; increase in marginal or expanded criteria donors Donor quality defined by post-transplant outcomes according to risk of graft loss (patient death or need for retransplantation)  Inferior organ quality engenders recipient morbidity and mortality

The Need for Innovation and Research in Donor Intervention and Treatment  To increase the number of organs available for transplantation Mitigate waitlist morbidity and mortality  To improve the quality of organs used for transplantation Mitigate recipient morbidity and mortality

Donor Recipients The Long Pathway for Donor-based Research Authorization/Consent IRB Approval Donor hospital “approval” Protocol dissemination Waitlist candidate / recipient consent Impact on allocation and distribution Recipient and transplant center outcomes Dissemination of study outcomes Safety and efficacy analyses Impact on donation

Obstacles to Research and Innovation in Deceased (Brain Dead) Donors  Scientific  Ethical  Logistical  Regulatory Investigator Donor / Donor hospitals OPOs Waitlist candidates Transplant recipients / centers

Problem Current ethical, logistical, and regulatory infrastructure is inadequate to support effective donor intervention and treatment studies. The magnitude and complexity of the challenges require guidelines to facilitate the optimal design and safe execution of clinical trials in deceased donors.

7/107/117/12 Initiative advanced by the Scientific Studies Committee Form working group to write Working Document in conjunction with Ethics and Standards/Quality Committees 1 st F2F Meeting ATC 2011 ASTS, AOPO, ODRC Share and Revise Working Document AST, AOPO, SCCM, ASBH 2 nd F2F Meeting ATC 2012 ASTS, AST, AOPO, SCCM, ODRC, and ODTA Discussions with Key Stakeholders Timeline of ASTS Efforts

Donor-based Issues Peter Abt

The Legal Basis for Research Authorization in Deceased (Brain Dead) Donors  Organ donation and associated research is based on gift law Donation is viewed as gifting, not as an informed decision regarding healthcare by the deceased or his / her next of kin

Specific Circumstances that Require Full Informed Consent  Genetic studies that risk Identification of the donor or Bears implications for the donor family  Precedent established by the National Disease Research Interchange Detailed informed consent related to genomics testing

Does Authorization Achieve Maximal Transparency?  Public perception of donation The importance of trust in the process Lack of awareness that donation may be associated with research Potential risk for research to alter the intention of the gift Varies with specific risk posed by each specific study

Donor Hospitals  All hospitals are potential donor hospitals There may, however, be as few as a single donor participating in any particular donor study  Donor hospitals have a vested interest in the appropriate assessment and conduct of research in deceased donors Public relations and perception Financial

Regulatory and Logistical Challenges Posed by Donor Hospitals  Most lack a policy for assessing clinical trial protocols in deceased donors Precedent of hospital DCD policy  If an investigator must approach each hospital on an individual basis – the current approach – donor-based research would be unfeasible

Regulatory Vacuum Related to Research in Deceased (Brain Dead) Donors  Federal regulations governing research in human subjects do not apply  The role of the institutional review board, if any, in the evaluation of donor intervention / treatment trials is unclear. Investigator OPO Donor hospital

Recipient-based Issues Sandy Feng

Potential Impact of Donor-based Research on Waitlist Candidates  Organ offers are made to waitlist candidates through their transplant physicians  Transplant physicians, in conjunction with candidates, must decide whether to accept or decline any / all organ offers  The exposure of an organ to an investigational intervention or treatment may impact the decision regarding acceptance or declination  The refusal of an organ secondary to concerns regarding donor research may lead to waitlist morbidity and / or mortality

Issues Related to Informed Consent in the Recipient  Receiving an organ that has been involved in a donor-based research protocol does NOT obligate the recipient to participate in the research  Donor-based research questions the necessity of recipient consent under specific circumstances Research with endpoints that relate solely to data derived from the deceased donor Research limited to the use of data submitted to the United Network for Organ Sharing and obtained without identifiers

Issues Related to Recipient Informed Consent  The necessity for informed consent depends on whether a person is a research subject Will there be interaction between the investigator and the organ recipient related to an investigational treatment? Will identifiable data be collected and/or analyzed for research purposes?  What might be the implications for donor intervention / treatment trials if organ recipients frequently decline consent to participate in research?

Logistical Challenges Related to Informed Consent for the Transplant Physician and Transplant Center  Transplant physicians will need to participate in and take responsibility for obtaining informed consent from the recipient for research participation Imposes an additional burden  The research protocol must be approved by the transplant center IRB Need for “IRB exemption” if center is not participating in the specific trial

The Need for Communication Mechanisms  A single repository that provides standardized information related to all donor-based studies (  A mechanism to expeditiously distribute detailed information about study interventions / treatments to the physicians of all candidates offered an organ from a donor that has participated in an intervention or treatment trial Essential for final decision regarding organ acceptance Essential to support informed consent discussion with the recipient regarding research participation  A mechanism to optimally and safely provide data regarding the recipient and/or transplant outcomes to the investigator

Safety and Efficacy Assessment

Impact on Organ Donation  Donor-based intervention and/or treatment trials may impact organ donation Negative impact if public perception views research as compromising the intent of the donor/donor family to bestow a gift through transplantation

Impact on Organ Allocation and Distribution  Declining to consider or accept organ offers secondary to donor-based research would alter organ allocation or distribution, respectively  The impact on individual and overall waitlist morbidity and mortality for all exposed organs must be assessed

Impact on Transplant Outcomes for All Exposed Organs  Donor intervention and treatment trials will likely be designed with a focus on collecting and analyzing data related to the outcome of a single organ However, multiple organs will likely have been exposed in the donor  The impact on the transplant outcomes of all exposed organs should be examined

Impact on Recipient-based Studies  Participation in a donor-based trial may exclude recipients of exposed organs from participation in other trials designed for transplant recipients  Transplant physicians and programs may harbor concerns about the imposition of these restrictions

Impact on Transplant Center Outcome Metrics  Donor intervention and treatment trials can impact statistics related to waitlist and transplant outcomes for transplant centers Performance metrics for OPOs and transplant centers are currently misaligned  These publicly available statistics, in turn, may risk a center’s reputation, accreditation, insurance contracting position, transplant volume, and revenue

What does the Organ Donation and Transplant Recipient Community Need? The ASTS requests that ACOT recommend to the Secretary that HRSA leadership work with the donation and transplantation community to provide recommendations that address the complex and multi-disciplinary challenges that obstruct the safe and optimal design and execution of innovative clinical trials in deceased brain dead organ donors.

Acknowledgements  ASTS Scientific Studies, Ethics, and Standards and Quality Committees  AST  AOPO/ODRC  SCCM  ASBH  ODTA